Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

HSV-2 Clinical Trial

Official title:
A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection

Status Completed

Clinical Trial Summary

The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

HSV-2

Clinical Trial Details

NCT number	NCT01047540
Study type	Interventional
Source	AiCuris Anti-infective Cures AG
Contact
Status	Completed
Phase	Phase 2
Start date	March 2010
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01108614` - Injecting Drug Use Community Intervention Trial	Phase 3
Completed	`NCT00803543` - Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrence and Viral Shedding	N/A
Completed	`NCT00274300` - Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2	Phase 1
Completed	`NCT00310271` - A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects	Phase 1